NEW YORK (GenomeWeb News) – Under an agreement announced on Monday, Wavi will apply its bioinformatics expertise to SomaLogic's proprietary proteomics assays.
Additionally, the two companies will plan two clinical studies in dementia that combines Wavi's electroencephalogram-based biomarkers and SomaLogic's blood-based protein biomarkers.
"Our mission is pre-symptomatic detection leading to early diagnosis enabling timely treatment of cognitive ailments," Stephen Onody, president and CEO of Wavi, said in a statement.
Financial and other terms of the deal were not disclosed.
The deal is the second in the past week announced by SomaLogic. Last week, the Boulder, Colo.-based company said it would provide New England Biolabs specific aptamer-based reagents for nucleic acid amplification and PCR products.